These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27254442)

  • 1. The value and impact of anti-Xa activity monitoring for prophylactic dose adjustment of low-molecular-weight heparin during pregnancy: a retrospective study.
    Boban A; Paulus S; Lambert C; Hermans C
    Blood Coagul Fibrinolysis; 2017 Apr; 28(3):199-204. PubMed ID: 27254442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case series of LMWH use in pregnancy: should trough anti-Xa levels guide dosing?
    Berresheim M; Wilkie J; Nerenberg KA; Ibrahim Q; Bungard TJ
    Thromb Res; 2014 Dec; 134(6):1234-40. PubMed ID: 25450535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular- weight heparin for the treatment of venous thromboembolism.
    Wilson SJ; Wilbur K; Burton E; Anderson DR
    Haemostasis; 2001; 31(1):42-8. PubMed ID: 11408748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study.
    Norris LA; Bonnar J; Smith MP; Steer PJ; Savidge G
    Thromb Haemost; 2004 Oct; 92(4):791-6. PubMed ID: 15467910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring of anti-Xa in pregnant patients with mechanical prosthetic valves receiving low-molecular-weight heparin: peak or trough levels?
    Goland S; Schwartzenberg S; Fan J; Kozak N; Khatri N; Elkayam U
    J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):451-6. PubMed ID: 24607762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Monitoring of low-molecular-weight heparins in pregnant women with inherited thrombophilic disorders].
    Paskaleva I; Karagiozova Zh; Doncheva E; Dineva D
    Akush Ginekol (Sofiia); 2014; 53(2):3-10. PubMed ID: 25098102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Xa Monitoring of Low-Molecular-Weight Heparin during Pregnancy: A Systematic Review.
    Kjaergaard AB; Fuglsang J; Hvas AM
    Semin Thromb Hemost; 2021 Oct; 47(7):824-842. PubMed ID: 34130342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Description of anti-Xa monitoring practices during low molecular weight heparin use.
    Lin A; Vazquez SR; Jones AE; Witt DM
    J Thromb Thrombolysis; 2019 Nov; 48(4):623-628. PubMed ID: 31317300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: single-center experience.
    Shapiro NL; Kominiarek MA; Nutescu EA; Chevalier AB; Hibbard JU
    Pharmacotherapy; 2011 Jul; 31(7):678-85. PubMed ID: 21923455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels.
    Gyamfi C; Cohen R; Desancho MT; Gaddipati S
    J Matern Fetal Neonatal Med; 2005 Nov; 18(5):329-31. PubMed ID: 16390793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjustment of therapeutic LMWH to achieve specific target anti-FXa activity does not affect outcomes in pregnant patients with venous thromboembolism.
    McDonnell BP; Glennon K; McTiernan A; O'Connor HD; Kirkham C; Kevane B; Donnelly JC; Ni Áinle F
    J Thromb Thrombolysis; 2017 Jan; 43(1):105-111. PubMed ID: 27517381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Placental Pathological Findings following Adjusting Enoxaparin Dosage in Thrombophilic Women: Secondary Analysis of a Randomized Controlled Trial.
    Garmi G; Zafran N; Okopnik M; Gavish I; Romano S; Salim R
    Thromb Haemost; 2019 Jan; 119(1):87-91. PubMed ID: 30597503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis.
    Fox NS; Laughon SK; Bender SD; Saltzman DH; Rebarber A
    Obstet Gynecol; 2008 Oct; 112(4):884-9. PubMed ID: 18827132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heparins].
    Marbet GA
    Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low molecular weight heparin in hemodialysis patients with a bleeding tendency.
    Leu JG; Chiang SS; Lin SM; Pai JK; Jiang WW
    Nephron; 2000 Dec; 86(4):499-501. PubMed ID: 11124600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of anti-Xa monitoring on the safety and efficacy of low-molecular-weight heparin anticoagulation therapy: A systematic review and meta-analysis.
    Wu T; Xia X; Chen W; Fu J; Zhang J
    J Clin Pharm Ther; 2020 Aug; 45(4):602-608. PubMed ID: 32449992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin generation assay identifies individual variability in responses to low molecular weight heparin in pregnancy: implications for anticoagulant monitoring.
    Chowdary P; Adamidou D; Riddell A; Aghighi S; Griffioen A; Priest P; Moghadam L; Kelaher N; Huq FY; Kadir RA; Tuddenham EG; Gatt A
    Br J Haematol; 2015 Mar; 168(5):719-27. PubMed ID: 25351814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic indications of low molecular weight heparins].
    Samama MM; Michaut-Paterno F
    Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.